Nutra Pharma Sponsors Climber with Rheumatoid Arthritis to Scale World's Highest Mountain
Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF), uses Nyloxin to manage pain on his quest to be the first climber with Rheumatoid Arthritis to scale Mount Everest.
January 18, 2010 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has sponsored Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF) on his attempt to be the first climber with Rheumatoid Arthritis (RA) to scale Mount Everest.
Gottfurcht has been using Nyloxin, Nutra Pharma’s newest Over-The-Counter treatment for Chronic Pain, to aid in relieving the pain and inflammation that accompanies rheumatoid arthritis. Nutra Pharma has supplied funding and Nyloxin as part of the sponsorship. In return, Gottfurcht will wear Nyloxin logo patches and carry Nyloxin flags and banners on the climb. Gottfurcht will take photographs and film the entire expedition and will provide dispatches from Mount Everest to his website, Facebook page and Nutra Pharma websites. Gottfurcht will also represent Nutra Pharma and Nyloxin during media events that take place after the climb.
Jeffrey Gottfurcht has been climbing mountains since his teens, but at 28 he was diagnosed with rheumatoid arthritis, an autoimmune disease which attacks the joints and causes; inflammation, joint pain and stiffness, while leading to fatigue and permanent joint damage. Buoyed by a personal quest and the goal of inspiring others, the 37 year-old founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF) and former finance executive, plans to be the first patient with RA to climb Mount Everest at 29,035 feet. Well before his RA diagnosis, Gottfurcht had conquered other peaks, including Mt. Elbrus (Russia, 18,500 feet), Mt. Rainier (Washington, 14,400 feet) and Pico de Orizaba (Mexico, 18,400 feet). Gottfurcht, the father of three young children, created the JGCAF, a wish-granting organization that grants dreams — ranging from requests to help cover educational and medical costs to requests for big screen computers or Wii systems to helping a child cope with limited visibility or mobility. Some dream requests are from juvenile arthritis patients seeking a moment to connect with a revered sports or pop culture icon to help them endure the intense pain of everyday life and medical treatment.
“We are pleased to sponsor Jeffrey on his historic Everest climb. We want people to become aware of rheumatoid arthritis and Jeffrey’s Foundation,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We want all chronic pain sufferers to understand that, if Nyloxin can be effective in this extreme use and in this extreme activity, imagine how effective it will be to manage their own everyday pain and inflammation. This sponsorship will prove invaluable to inform chronic pain sufferers and medical professionals of the power and efficacy of Nyloxin, as well as building awareness of Juvenile Rheumatoid Arthritis,” he added.
Nyloxin, which was first introduced in November 2009 as a treatment for moderate to severe, Stage 2, chronic pain, is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
“It’s been a pleasure working with Nutra Pharma as I’ve been planning my climb,” commented Jeffrey Gottfurcht. “I have seen some personal benefits in using Nyloxin on my own pain, stiffness and inflammation. Most drugs for rheumatoid arthritis have side effects, including loss of mental function, which would make the climb even more difficult. Nyloxin lacks these side-effects, making it much easier to use,” he added.
Gottfurcht, who lives in the San Francisco area, will begin his journey to the world's highest mountain in the Spring of 2011, accompanied by a guide and a Sherpa on what is typically a six-week climb, subject to favorable weather conditions.
The Jeffrey Gottfurcht Children’s Arthritis Foundation was founded by Jeffrey Gottfurcht as a way to inspire, educate and generate awareness of both rheumatoid and juvenile idiopathic arthritis, as those suffering optimistically await a cure. In 2002, at the age of 28, Gottfurcht was diagnosed with RA and after undergoing years of treatment; he wanted to share his determination to fight the disease while bringing joy, strength and support to children and young adults similarly afflicted. A wish-granting Foundation, JGCAF accepts referrals for dreams from parents, guardians, siblings, members of the medical community, and directly from children suffering from juvenile rheumatoid arthritis. The Foundation’s Dream Team helps select dreams that are prudent and possible and assists in making them come true. Help us fulfill a dream of a child living with Juvenile Arthritis today. For more information please call 310.855.3745 or visit www.JGCAF.org.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Providing RPI-78M under compassionate release to patients enrolled in the Adrenomyeloneuropathy (AMN) clinical study should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.